Evidence map›Paper›PMID 42922261›Full record

ArticleJournal of diabetes research2026

The AGEs/RAGE Axis Contributes to Myocardial Cell Death in Type 1 Diabetic Cardiomyopathy via the ROS/NF-κB/NLRP3 Inflammasome Pathway.

Xiaoqun Li, Shujie Chen, Ke Wang, Ke Xu, Yannan Wang, Zechao Zhang, Xue Liu

Abstract read
In one paragraph

Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoqun LiState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0008-4741-8689
Shujie ChenState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0008-3914-3566
Ke WangState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0005-7712-3652
Ke XuState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0002-2238-4992
Yannan WangState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0006-1547-4817
Zechao ZhangState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0002-4171-5830
Xue LiuState-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China, hrbmu.edu.cn.ORCID https://orcid.org/0009-0004-1879-3851

Funding

Chunyan Team Programme of Heilongjiang Province CYQN24043National Natural Science Foundation of China 81700220Postdoctoral Startup Foundation of Heilongjiang Province 21042230016
6 · The paper itself

Abstract

backgroundType 1 diabetes mellitus (T1DM) cardiomyopathy is a severe complication that typically follows an insidious onset and then progresses rapidly to heart failure and premature death. AGEs accumulate in the myocardium under hyperglycemic conditions and have emerged as important mediators of this diabetic complication, although the full signaling cascades engaged by AGEs remain largely unresolved. In the present study, we therefore investigated whether AGEs induce myocardial injury in T1DM via NLRP3 inflammasome activation.

methodsA T1DM mouse model was established using streptozotocin (STZ) injections, and an in vitro model was generated by treating primary neonatal mouse cardiomyocytes with AGEs. Cardiac performance and morphological changes were examined via echocardiography and histopathological staining. Expression and activation of the NLRP3 signaling cascade were evaluated by Western blotting, ELISA, and immunofluorescence. Pyroptotic cell death was assessed by SYTOX green staining, PI uptake, and lactate dehydrogenase (LDH) release assay. Correlations between whole-blood RAGE gene expression and inflammatory cytokine levels (IL-1β and IL-18) in T1DM patients, along with myocardial abundance of RAGE, NLRP3, and N-GSDMD in the experimental mice, were analyzed as exploratory descriptive observations.

resultsSTZ-induced T1DM mice exhibited sustained hyperglycemia (fasting blood glucose ≥ 11.1 mmol/L) and impaired cardiac function. Myocardial tissue from T1DM animals showed marked engagement of the NLRP3 signaling cascade, as evidenced by elevated NLRP3, cleaved caspase-1 P20, and N-GSDMD, enhanced ASC speck formation, and increased serum IL-1β levels. In vitro, AGEs treatment directly triggered the NLRP3 pathway and drove cardiomyocyte pyroptosis. Mechanistically, AGEs binding to RAGE triggered a burst of intracellular ROS, which led to NF-κB activation and subsequent NLRP3 activation. These effects were suppressed by either the RAGE inhibitor FPS-ZM1 or the ROS scavenger N-acetylcysteine (NAC). Furthermore, MCC950 treatment significantly attenuated AGE-induced caspase-1 activation, IL-1β/IL-18 secretion, and N-GSDMD expression, confirming that NLRP3 is a necessary mediator of this signaling cascade. SYTOX green staining, PI uptake, and LDH release assays further demonstrated that AGE-induced pyroptotic cell death was blocked by FPS-ZM1, NAC, and MCC950, indicating that pyroptosis occurs specifically through the RAGE/ROS/NLRP3 axis. Correlation analyses revealed that RAGE transcript levels in whole blood from T1DM patients positively correlated with circulating IL-1β and IL-18. In the diabetic mouse heart, RAGE, NLRP3, and N-GSDMD protein levels were analyzed as exploratory descriptive observations and showed a consistent pattern of coexpression at the individual level.

conclusionAGEs promote NLRP3 inflammasome activation in cardiomyocytes via the RAGE/ROS/NF-κB signaling axis, driving inflammatory responses and pyroptosis, thereby contributing to the progression of T1DM cardiomyopathy. These observations imply that modulating this signaling axis could serve as a promising therapeutic strategy for treating T1DM cardiomyopathy.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Diabetic CardiomyopathiesGlycation End Products, AdvancedInflammasomesMyocytes, CardiacNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinReactive Oxygen SpeciesReceptor for Advanced Glycation End ProductsAnimalsCell DeathHumansInterleukin-1betaMaleMiceAger protein, mouseGlycation End Products, AdvancedInflammasomesInterleukin-1betaNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseReactive Oxygen SpeciesReceptor for Advanced Glycation End Productsadvanced glycation end products (AGEs)diabetic cardiomyopathyNLRP3 inflammasomeType 1 diabetes mellitus

Identifiers

PMID42922261
PMCPMC13691523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.